Skip to main content

#161966

DuCap 1 [source] Cell line

Cat. #161966

DuCap 1 [source] Cell line

Cat. #: 161966

Availability: 8-10 weeks

Organism: Human

Tissue: Prostate

Disease: Cancer

Model: Tumour Cell Line

£575.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Wytske van Weerden

Institute: Erasmus University Medical Centre

Primary Citation: Moll JM et al. 2022. Front. Oncol. Jun 13,12:877613. PMID: 35769712

Tool Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: DuCap 1 [source] Cell line
  • Research fields: Cancer
  • Organism: Human
  • Tissue: Prostate
  • Disease: Cancer
  • Model: Tumour Cell Line
  • Receptors of note: Androgen receptor
  • Description: CRPC DuCap cell line series - source (source cell line from which sublines were made resistant to Bicalutamide through long-term passaging). DuCap is a human prostate cancer cell line that expresses wild-type androgen receptor (AR), this cell line has been used as a model to study AR signalling in prostate cancer. This cell line is the source cell line from which a series of DuCap CRPC models were generated.
  • Application: Tumour Modelling

Applications

  • Application: Tumour Modelling

Handling

  • Growth medium: RPMI1640 + 10% FCS
  • Storage conditions: liquid N2
  • Cultured in antibiotics: 1% Penicillin/Streptomycin

References

  • Moll JM et al. 2022. Front. Oncol. Jun 13,12:877613. PMID: 35769712

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.